中國平安持續調高現金分紅 2021年每股股息同比提升8.2%
格隆匯3月17日丨中國平安(2318.HK,601318.SH)公佈2021年全年業績。2021年,平安整體業績保持穩健增長,實現歸屬於母公司股東的營運利潤1479.61億元,同比增長6.1%;營運ROE達18.9%。
平安注重股東回報,持續調高現金分紅,向股東派發全年股息每股現金人民幣2.38元,同比增長8.2%。公司於2021年8月啟動新一輪股票回購方案,截至2021年12月末已回購約7777萬股,共計近39億元。
注:中國平安今日A股收漲2.73%報45.5元,H股尾盤出現快速拉昇,最終收漲10.49%報55.3港元;中國平安AH股均為連續第二日反彈,且明顯強於大盤。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.